Evidence map›Paper›PMID 39136764›Full record

ArticleZeitschrift fur Rheumatologie2024

[Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].

J Braun, K Albrecht, J Callhoff, I Haase, A Krause, H-J Lakomek, D Meyer-Olson, R Schmale-Grede, U Wagner, J Zeidler and 4 more

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

J BraunDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland.
K AlbrechtProgrammbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Deutschland.
J CallhoffProgrammbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Deutschland.
I HaaseDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland.
A KrauseDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland.
H-J LakomekUniversitätsklinik für Geriatrie, Johannes Wesling Klinikum Minden, Minden, Deutschland.
D Meyer-OlsonKlinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
R Schmale-GredeDeutsche Rheuma-Liga, Bundesverband, Bonn, Deutschland.
U WagnerDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland.
J ZeidlerCenter for Health Economics Research Hannover (CHERH), Leibniz Universität Hannover, Hannover, Deutschland.
S ZinkeRheumatologische Schwerpunktpraxis, Berlin, Berlin, Deutschland.
A VoormannDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland. anna.voormann@dgrh.de.
C SpeckerDeutsche Gesellschaft für Rheumatologie und Klinische Immunologie e. V. (DGRh), Wilhelmine-Gemberg-Weg 6, Aufgang C, 10179, Berlin, Deutschland.
die Kommission Versorgung der DGRh

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatology in Germany is facing major challenges. The need for rheumatological care is increasing and can no longer be met in some regions for capacity reasons. Too many people with an inflammatory rheumatic disease (IRD) have to forego appropriate care or receive it too late. The 4th new edition of the memorandum of the German Society for Rheumatology and Clinical Immunology (DGRh) provides information on rheumatological care in Germany. It was produced under the leadership of the DGRh together with the Professional Association of German Rheumatologists (BDRh), the Association of Acute Rheumatology Clinics (VRA), the German Rheumatism League (DRL) and the German Rheumatism Research Center (DRFZ).

methodsThe memorandum describes the current state and development of the following areas: number of people with IRD, outpatient, inpatient and rehabilitative care structures, number of specialists in rheumatology, education and training, quality of care, health economic aspects and digital care concepts. Proposals for health policy measures to safeguard rheumatological care are presented.

resultsPrevalence: approximately 1.8 million adults in Germany have an IRD. The prevalence is increasing, due to changes in the demographic structure of the population, improved diagnostics, treatment and longer survival. Care structures: outpatient specialist care (ASV) for rheumatic diseases is developing as a cross-sectoral care model for hospital outpatient clinics and rheumatology practices. Hospitals have been able to be certified as rheumatology centers since 2020, which enables structural developments. Specialists in rheumatology: as of 31 December 2023, there were 1164 specialists in rheumatology working in Germany. This included 715 physicians accredited to work in practices for national health assurance patients, 39% of whom were employees. In hospitals, 39% of doctors worked part-time. At least 2 rheumatology specialists per 100,000 adults are needed, i.e. around 1400, in order to provide adequate care. This means that there is a shortage of around 700 rheumatology specialists in the outpatient sector alone. Of all working specialists, 30% are currently aged 60 years old and over. Medical training: only 10 out of 38 (26%) state universities have an independent chair in rheumatology. In addition, 11 rheumatology departments are subordinate to a nonrheumatology chair. In the rheumatology-integration into student training (RISA) III study, only 16 out of 36 faculties fulfilled the recommended minimum number of compulsory hours of student rheumatology teaching. Continuing education in rheumatology: the annual postgraduate training qualifications do not cover the demand for rheumatology specialists, which is additionally increasing due to intensified workload, reduced capacities through retirement, and part-time work. Quality of care: since the introduction of highly effective medication patients with IRD have a much better chance of achieving remission of their disease. With early initiation of targeted therapy, the lives of many patients are hardly restricted at all: however, waiting times for a first rheumatological visit often last more than 3 months. Quality target is a first consultation within the first 6 weeks after the onset of symptoms. Models for early consultation, delegation of medical services, structured patient training and digital care concepts have been positively evaluated but are not covered financially. COSTS: the total annual costs for inflammatory joint diseases alone amount to around 3 billion euros. The direct costs have significantly risen since the introduction of biologics, while the indirect costs for sick leave, disability and hospitalization have fallen.

conclusionThe core demands of this memorandum are a significant and sustainable increase in the number of further training positions in the outpatient and inpatient sector, the creation of chairs or at least independent departments for rheumatology at all universities and the further implementation of new and cross-sectoral forms of care. This will ensure modern needs-based rheumatological care for all patients in the future.

Indexed as

Rheumatic DiseasesRheumatologyAllergy and ImmunologyDelivery of Health CareForecastingGermanyHumansSocieties, MedicalInpatient careMedical costsOutpatient careQuality of careRheumatology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.